Fineline Cube

Follow:
14419 Articles
MSD Reports 3% YoY Q3 2025 Sales Growth, Keytruda Drives 8% Lift, Verona Acquisition Strengthens Cardio‑Pulmonary Portfolio
Company

MSD Reports 3% YoY Q3 2025 Sales Growth, Keytruda Drives 8% Lift, Verona Acquisition Strengthens Cardio‑Pulmonary Portfolio

Eli Lilly Reports 54% YoY Revenue Surge in Q3 2025, Raises Full‑Year Guidance to $63 B
Company

Eli Lilly Reports 54% YoY Revenue Surge in Q3 2025, Raises Full‑Year Guidance to $63 B

Jebel Pharma Reports Positive Phase III Results for JJH201501 Antidepressant
CompanyDrug

Jebel Pharma Reports Positive Phase III Results for JJH201501 Antidepressant

Shanghai Bio‑Heart’s Iberis RDN System Gains UK MHRA Approval, Expands Global Commercial Reach
CompanyMedical Device

Shanghai Bio‑Heart’s Iberis RDN System Gains UK MHRA Approval, Expands Global Commercial Reach

Transcenta Partner Inhibrx Reports Positive ChonDRAgon Results for Ozekibart, Plans FDA BLA Filing in 2026
CompanyDrug

Transcenta Partner Inhibrx Reports Positive ChonDRAgon Results for Ozekibart, Plans FDA BLA Filing in 2026

HighTide Therapeutics Announces Positive Phase III Results for HTD1801 in Type 2 Diabetes
CompanyDrug

HighTide Therapeutics Announces Positive Phase III Results for HTD1801 in Type 2 Diabetes

Takeda Reports 3.9% YoY Revenue Decline in H1 2025, Citing Neuroscience Slump and FX Headwinds
Others

Takeda Reports 3.9% YoY Revenue Decline in H1 2025, Citing Neuroscience Slump and FX Headwinds

BrightGene Submits HKEX Prospectus, Aiming for Main‑Board Listing
CompanyDeals

BrightGene Submits HKEX Prospectus, Aiming for Main‑Board Listing

Dizal Pharmaceutical Reports 73% Revenue Growth, Driven by Sunvozertinib and Golidocitinib
Company

Dizal Pharmaceutical Reports 73% Revenue Growth, Driven by Sunvozertinib and Golidocitinib

JW Therapeutics & Regeneron Sign Expanded TCR‑T Collaboration, Unlocking $50 Million in Funding
CompanyDeals

JW Therapeutics & Regeneron Sign Expanded TCR‑T Collaboration, Unlocking $50 Million in Funding

Novo Nordisk Launches $9 Billion Unsolicited Bid for Metsera, Triggering Battle with Pfizer
CompanyDeals

Novo Nordisk Launches $9 Billion Unsolicited Bid for Metsera, Triggering Battle with Pfizer

Thermo Fisher Secures $8.875B Clario Acquisition, Enhancing Digital‑Trial Endpoint Suite
CompanyDeals

Thermo Fisher Secures $8.875B Clario Acquisition, Enhancing Digital‑Trial Endpoint Suite